Science News
from research organizations

Science behind treating patients with corneal blindness advanced

Date:
January 27, 2015
Source:
Cedars-Sinai Medical Center
Summary:
A novel way to generate transplantable corneal stem cells has been developed, and may eventually benefit patients suffering from life-altering forms of blindness. The research marks an important first step toward creating a bank of corneal stem cells that may potentially benefit patients who suffer from many forms of corneal blindness.
Share:
FULL STORY

Researchers in the Cedars-Sinai Board of Governors Regenerative Medicine Institute have devised a novel way to generate transplantable corneal stem cells that may eventually benefit patients suffering from life-altering forms of blindness.

Scientists used human corneal cells to generate pluripotent stem cells that have a capacity to become virtually any body cell. Then, putting these cells on natural scaffolds, researcher's facilitated differentiation of these stem cells back to corneal cells.

"Our research shows that cells derived from corneal stem cells are attractive candidates for generating corneal cells in the laboratory," said Alexander Ljubimov, PhD, director of the Eye Program at the Board of Governors Regenerative Medicine Institute and principal investigator on this research study.

This research, published in the journal Stem Cells Translational Medicine, marks an important first step toward creating a bank of corneal stem cells that may potentially benefit patients who suffer from many forms of corneal blindness. The group is now working to optimize the process with National Institutes of Health funding.

Corneal deficiencies may have genetic or inflammatory roots or be caused by injuries, like burns to the skin in occupational accidents. They result in damage or death of stem cells that renew the outermost part of the cornea. If left untreated, they often cause compromised vision or blindness.

Over 150,000 Americans and more than 3 million individuals worldwide are affected by corneal blindness.

Study collaborators include Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and professor of biomedical sciences and medicine; Dhruv Sareen, PhD, director of the Induced Pluripotent Stem Cell Core and assistant professor of biomedical sciences; Mehrnoosh Saghizadeh, PhD, assistant professor of biomedical sciences; Yaron Rabinowitz, MD, director of the Division of Ophthalmology Research; and Vincent A. Funari, PhD, director of the Genomics Core and assistant professor of pediatrics.


Story Source:

Materials provided by Cedars-Sinai Medical Center. Note: Content may be edited for style and length.


Journal Reference:

  1. D. Sareen, M. Saghizadeh, L. Ornelas, M. A. Winkler, K. Narwani, A. Sahabian, V. A. Funari, J. Tang, L. Spurka, V. Punj, E. Maguen, Y. S. Rabinowitz, C. N. Svendsen, A. V. Ljubimov. Differentiation of Human Limbal-Derived Induced Pluripotent Stem Cells Into Limbal-Like Epithelium. Stem Cells Translational Medicine, 2014; 3 (9): 1002 DOI: 10.5966/sctm.2014-0076

Cite This Page:

Cedars-Sinai Medical Center. "Science behind treating patients with corneal blindness advanced." ScienceDaily. ScienceDaily, 27 January 2015. <www.sciencedaily.com/releases/2015/01/150127164848.htm>.
Cedars-Sinai Medical Center. (2015, January 27). Science behind treating patients with corneal blindness advanced. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2015/01/150127164848.htm
Cedars-Sinai Medical Center. "Science behind treating patients with corneal blindness advanced." ScienceDaily. www.sciencedaily.com/releases/2015/01/150127164848.htm (accessed May 23, 2017).

RELATED STORIES